# US 2008/0305508 A1 · Methods of screening for compounds that modulate TAFIa activity, compounds, and methods of using the compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305508 A1
- Document ID: US20080305508A1
- Status: Published application
- Kind: A1
- Application number: 11/544,906
- Filed: 2006-10-06
- Published: 2008-12-11
- Earliest claimed: 2002-08-29
- Assignees: American Diagnostica, Inc.
- Inventors: Robert S. Greenfield; Seong Soo A. An; Latchezar Trifonov; Jean Vaugeois; Clarke Slemon
- Web page: https://patentgrep.com/patent/US20080305508A1

## CPC

- C12Q 1/37: involving peptidase or proteinase
- A61K 31/60: Salicylic acid; Derivatives thereof
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/06: Antianaemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C12Q 1/56: involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- G01N 33/9486: {Analgesics, e.g. opiates, aspirine}
- G01N 2500/00: Screening for compounds of potential therapeutic value
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites. Also contemplated is a method of treating, preventing or managing in a patient, pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder comprising administering aspirin or a derivative thereof or any other therapeutic having at least one desired therapeutic or prophylactic activity of aspirin to a patient in need thereof and administering to the patient a factor that promotes TAFIa activity, e.g. stabilized TAFIa, to ameliorate one or more adverse side effects of the therapeutic. Compounds identified by the methods of the invention are also provided.

## Claims

### Claim 1

A method of identifying a compound which possesses (i) at least one aspirin activity selected from the group consisting of analgesia, anti-inflammation, fever reduction, COX-1 inhibition, COX-2 inhibition, anti-platelet aggregation and pancreatic cancer prophylaxis, and (ii) no TAFIa-inhibition, comprising the steps of:
a) exposing TAFIa to the test compound;
b) determining whether the test compound inhibits TAFIa activity and/or inhibits TAFI activation; and
c) determining whether at least one aspirin activity is retained by the test compound, thereby identifying a compound that possesses at least one aspirin activity but not TAFIa-inhibitory activity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the aspirin activity is COX-2 inhibition.

### Claim 3 (depends on 1)

The method of claim 1, wherein the aspirin activity is COX-1 inhibition.

### Claim 4 (depends on 1)

The method of claim 1, wherein the aspirin activity is analgesia.

### Claim 5 (depends on 1)

The method of claim 1, wherein the aspirin activity is fever reduction.

### Claim 6 (depends on 1)

The method of claim 1, wherein the aspirin activity is anti-inflammation.

### Claim 7 (depends on 1)

The method of claim 1, wherein the aspirin activity is anti-platelet aggregation.

### Claim 8 (depends on 1)

The method of claim 1, wherein the aspirin activity is colon cancer prophylaxis.

### Claim 9 (depends on 1)

The method of claim 1, wherein the aspirin activity is pancreatic cancer prophylaxis.

### Claim 10 (depends on 1)

A method of treating pain, fever, inflammation, platelet-aggregation, colon cancer, pancreatic cancer, fibrinolytic, or thrombotic disease or disorder in a patient in need thereof, comprising administering a compound identified by the method of claim 1 to the patient.

### Claim 11

A method of evaluating inhibition of TAFIa activity by a test compound, in comparison with aspirin, salicylic acid, salicyluric acid or gentisic acid, comprising the steps of:
a) exposing TAFIa to the test compound;
b) measuring inhibition of TAFIa activity by the test compound; and
c) comparing the inhibition of TAFIa activity by the test compound to inhibition of TAFIa activity by aspirin, SA, SU or gentisic acid,
thereby determining whether the test compound inhibits TAFIa activity more or less than aspirin, salicylic acid, salicyluric acid or gentisic acid.

### Claim 12 (depends on 11)

A compound identified by the method of claim 11.

### Claim 13 (depends on 11)

The method of claim 11, wherein an inhibitor of TAFIa is identified if the test compound inhibits TAFIa activity as compared to aspirin, salicylic acid, salicyluric acid or gentisic acid.

### Claim 14 (depends on 11)

The method of claim 11, wherein step (a) further comprises preincubating TAFIa and the test compound for at least about 20 minutes.

### Claim 15 (depends on 11)

The method of claim 11, wherein step (b) is carried out using a clot lysis assay.

### Claim 16 (depends on 11)

The method of claim 11, wherein step (b) is carried out using a fibrinogen assay.

### Claim 17 (depends on 11)

The method of claim 11, wherein step (b) is carried out using a plasminogen capture assay.

### Claim 18 (depends on 11)

The method of claim 11, wherein step (b) comprises using a fluorescent based assay.

### Claim 19

A method of inhibiting TAFIa carboxypeptidase activity in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a TAFIa inhibiting compound selected from the group consisting of acetylsalicylic acid, salicylic acid, salicyluric acid, gentisic acid, glycyl amides and α-hydroxybenzoate derivatives, in an amount effective to inhibit TAFIa activity.

### Claim 20 (depends on 19)

The method of claim 19, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

### Claim 21

A method of treating or managing a thrombotic disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an inhibitor of TAFIa, wherein said inhibitor is selected from the group consisting of salicylic acid, salicyluric acid, gentisic acid, glycyl amides, acetylsalicylic acid and α-hydroxybenzoate derivatives, in an amount effective to inhibit TAFIa activity.

### Claim 22 (depends on 21)

The method of claim 21, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

### Claim 23 (depends on 21)

The method of claim 21, wherein the thrombotic disease or disorder is selected from the group consisting of angina pectoris, chronic stable angina pectoris, heart attack, stroke, thromboembolic disease, myocaridal infarction (MI), acute myocardial infarction (AMI), recurrent myocardial infarction, ischemic attack, transient ischemic attack (TIA), deep vein thrombosis, acute ischemic stroke, massive pulmonary embolism, disseminated intravascular coagulation (DIC), anti-phospholipid syndrome, familial thrombophilia, sepsis, arthritis, fulminant hepatitis, thrombosis, hemophilia and Von Willebrand disease.

### Claim 24

A method of preventing a thrombotic disorder in a patient, comprising administering to the patient a prophylactically effective amount of an inhibitor of TAFIa, wherein said inhibitor is selected from the group consisting of salicylic acid, salicyluric acid, gentisic acid, glycyl amides, acetylsalicylic acid and α-hydroxybenzoate derivatives.

### Claim 25 (depends on 24)

The method of claim 24, wherein said inhibitor of TAFIa is formulated with a pharmaceutically acceptable carrier.

### Claim 26 (depends on 24)

The method of claim 24, wherein the thrombotic disorder is angina pectoris, chronic stable angina pectoris, heart attack, stroke, thromboembolic disease, myocaridal infarction (MI), acute myocardial infarction (AMI), recurrent myocardial infarction, ischemic attack, transient ischemic attack (TIA), deep vein thrombosis, acute ischemic stroke, massive pulmonary embolism, disseminated intravascular coagulation (DIC), anti-phospholipid syndrome, familial thrombophilia, sepsis, arthritis, fulminant hepatitis, or thrombosis.

### Claim 27

A method of reducing bleeding side-effects of aspirin in a patient, said method comprising administering stabilized TAFIa to a patient receiving aspirin therapy.

### Claim 28 (depends on 27)

The method of claim 27, wherein aspirin is administered prior to, subsequent to, or concurrently with said administration of stabilized TAFIa.

### Claim 29 (depends on 19, 21, 24, 27)

The method of one of claims 19, 21, 24 or 27 further comprising surgery on the patient.

### Claim 30 (depends on 29)

The method of claim 29, wherein the surgery is selected from the group consisting of organ transplant surgery, cardiopulmonary bypass surgery, coronary angioplasty, open heart surgery, heart valve surgery and removal of atherosclerotic plaques.

### Claim 31 (depends on 19, 21, 24, 27, 28, 29, 30)

The method of one of claims 19, 21, 24, 27-30 further comprising administering an anti-coagulant to the patient.

### Claim 32 (depends on 31)

The method of claim 31, wherein the anti-coagulant is selected from the group consisting of tissue plasminogen activator, heparin, low molecular weight heparin, aspirin, actothrombin, hirudin, plasminogen, streptokinase, staphylokinase, urokinase and hirulong.

### Claim at position 33

33-37. (canceled)

### Claim 38

A method of treating or managing a thrombotic disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a compound having the chemical structure selected from the group consisting of:
in an amount effective to inhibit TAFIa activity.

### Claim 39 (depends on 38)

The method of claim 38, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

### Claim 40 (depends on 38)

The method of claim 38, wherein the thrombotic disease or disorder is selected from the group consisting of angina pectoris, chronic stable angina pectoris, heart attack, stroke, thromboembolic disease, myocaridal infarction (MI), acute myocardial infarction (AMI), recurrent myocardial infarction, ischemic attack, transient ischemic attack (TIA), deep vein thrombosis, acute ischemic stroke, massive pulmonary embolism, disseminated intravascular coagulation (DIC), anti-phospholipid syndrome, familial thrombophilia, sepsis, arthritis, fulminant hepatitis, thrombosis, hemophilia and Von Willebrand disease.

### Claim 41

A method of preventing a thrombotic disorder in a patient, comprising administering to the patient a pharmaceutical composition comprising a compound having the chemical structure selected from the group consisting of:
in an amount effective to prevent the thrombotic disorder.

### Claim 42 (depends on 41)

The method of claim 41, wherein pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

### Claim 43 (depends on 41)

The method of claim 41, wherein the thrombotic disorder is selected from the group consisting of angina pectoris, chronic stable angina pectoris, heart attack, stroke, thromboembolic disease, myocaridal infarction (MI), acute myocardial infarction (AMI), recurrent myocardial infarction, ischemic attack, transient ischemic attack (TIA), deep vein thrombosis, acute ischemic stroke, massive pulmonary embolism, disseminated intravascular coagulation (DIC), anti-phospholipid syndrome, familial thrombophilia, sepsis, arthritis, fulminant hepatitis, or thrombosis.

### Claim 44 (depends on 38, 41)

The method of one of claims 38 or 41, further comprising surgery on the patient.

### Claim 45 (depends on 44)

The method of claim 44, wherein the surgery is selected from the group consisting of organ transplant surgery, cardiopulmonary bypass surgery, coronary angioplasty, open heart surgery, heart valve surgery and removal of atherosclerotic plaques.

### Claim 46 (depends on 38, 41)

The method of one of claims 38 or 41, further comprising administering an anti-coagulant to the patient.

### Claim 47 (depends on 46)

The method of claim 46, wherein the anti-coagulant is selected from the group consisting of tissue plasminogen activator, heparin, low molecular weight heparin, aspirin, actothrombin, hirudin, plasminogen, streptokinase, staphylokinase, urokinase and hirulong.
